Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-01

Clinical Trial Update: Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating betaine to reduce urine oxalate in patients with Type 1 primary hyperoxaluria. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Betaine (betaine (trimethylglycine))

Snippet

Sponsor: Mayo Clinic | Conditions: Hyperoxaluria | Phase 2 | Status: COMPLETED | Results posted: 2013-01-01